Sunday November 22 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

Micromet Inc.

Micromet, Inc. (NASDAQ: MITI) is a transatlantic biopharmaceutical company formed through the mergerof Micromet AG and CancerVax, Inc. in May 2006.Focused on the development and design of novel antibody derived drugs, the Company has built a wellstaged pipeline of highly differentiated products for the treatment of cancer, inflammation and autoimmune diseases. Micromet´s strong pipeline-generating and evelopmental capabilities have enabled the Company to pursue a growth-oriented business strategy and to generate ignificant revenues through partnerships with companies like Serono and MedImmune, Inc. In parallel,Micromet has consolidated key intellectual property in the antibody sector, secured a strong IP osition on its candidates and technologies and established an active out-licensing business for single-chain antibody technology.


Contact Details:
2110 Rutherford Road
Carlsbad
California
92008
United States of America
Tel:(760) / 494-4200
Fax:(760) / 431-9980
Email:info@micromet-inc.com
WWW:

www.micromet.de/




Loading...

Recent Publications by Micromet Inc.:

Bispecific T-cell engaging antibodies for cancer therapy.
There is increasing evidence that T cells are able to control tumor growth...
7th July, 2009
Micromet Inc., Bethesda, Cancer Res. 2009 Jun 15;69(12):4941-4. Epub 2009 Jun 9.
DOI Direct Link
BiTE: Teaching antibodies to engage T-cells for cancer therapy.
Bispecific T-cell-engager (BiTE) antibodies are designed to transiently...
27th March, 2009
Micromet Inc, 6707 Democracy Boulevard, Suite 505, Bethesda, MD 20817, Curr Opin Mol Ther. 2009 Feb;11(1):22-30.
EpCAM (CD326) finding its role in cancer.
Although epithelial cell adhesion/activating molecule (EpCAM/CD326) is one...
22nd March, 2007
Micromet, Inc., 2110 Rutherford Road, Carlsbad, CA, 92008, USA. Br J Cancer. 2007 Feb 12;96(3):417-23. Epub 2007 Jan 9.
DOI Direct Link

Press Releases on Micromet Inc.:

BioPortfolio Logo
Micromet to Present at The 8th Annual BIO Investor Forum Conference on October 29, 2009 21st October, 2009 Micromet, Inc.
BETHESDA, Md., Oct. 21 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and
DOR BioPharma Appoints Christopher P. Schnittker, CPA, as Vice President of Administration and Controller 7th July, 2009 DOR BioPharma, Inc.
PRINCETON, N.J., July 7 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biopharmaceutical company, announced today that it recently
Micromet Added to Russell 3000 Index 29th June, 2009 Micromet, Inc.
BETHESDA, Md., June 29 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and
Phase 1 Study Initiated with Micromet Anti-GM-CS Human Antibody MT203 18th June, 2009 Micromet, Inc.
BETHESDA, Md., June 18 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and
Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients 8th June, 2009 Micromet, Inc.
German Multicenter ALL Study Group Presented Data at the 14th Congress of the European Hematology Association Showing High Response Rate in Patients with Minimal Residual Disease BERLIN, June 8

BioNews Results for Micromet Inc.:

Micromet to Present at The Lazard Capital Markets 6th Annual Healthcare Conference on November 18, 2009
Stockwatch:  Nov 12 2009 8:20PM Matching: micromet inc
Micromet to Present at The Lazard Capital Markets 6th Annual Healthcare Conference on November 18, 2009
NewsBlaze:  Nov 12 2009 8:36PM Matching: micromet inc
Micromet to Present at The Lazard Capital Markets 6th Annual Healthcare Conference on November 18, 2009
NewsBlaze:  Nov 12 2009 8:36PM Matching: micromet inc
Micromet Buys Out MedImmunes Remaining Rights to Blinatumomab
Bionity.com:  Nov 11 2009 1:27AM Matching: micromet inc
Micromet Buys Out MedImmune's Remaining Rights to Blinatumomab
Bionity.com:  Nov 10 2009 11:05PM Matching: micromet inc
Promote your company here: BioNewsCast - Press Release Distribution

View more Micromet Inc. news.

Micromet Inc. (MITI) Financial information Links from Barchart

MITI Quote from from Barchart.com
MITI Chart from from Barchart.com
MITI Profile from from Barchart.com
MITI Opinion from from Barchart.com

View more Micromet Inc. finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 496 times since April 2007, the link to the organisation's website has been followed 89 times

Recent Search Terms used to find this page: micromet intellectual property | micromet inc. | Micromet carlsbad | BiTe Micromet Linker | Micromet Inc | micromet news september 2009 | micromet | 6707 Democracy Boulevard, Suite 505, Bethesda, MD, 20817 | bispecific t engage antibody linker | Micromet Inc. | .

Search for more companies in Carlsbad

Search for more companies in California



This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Micromet Inc.

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.